All posts tagged "Yeztugo"
-
Injectable PrEP Does Not Interfere With Hormone Therapy
A study suggests twice-yearly Yeztugo offers HIV prevention without adversely affecting gender-affirming care.
-
CVS Health Refuses to Cover Cost of Twice-a-Year Injectable PrEP
CVS refused to cover Yeztugo, Gilead’s $28,000-a-year injectable PrEP, preventing patients from accessing the HIV prevention drug at no cost.
-
FDA Approves PrEP Drug Requiring Only Two Injections Per Year
FDA approves PrEP drug. Lenacapavir is a twice-yearly HIV prevention shot more effective than daily pills.
